 Erwinaze will be administered intravenously at a dose of 25,000 IUm2 dose cohort 0 for 6 doses MWF over a period of 2 weeks to 9 patients as described below and in the following schema. Blood counts, chemistries including bilirubin, amylase and lipase, and coagulation studies including fibrinogen will be measured and reviewed before each asparaginase dose. Fibrinogen 100 mgdL can be replaced with cryoprecipitate before each dose at the discretion of treating physician. Treatment will be stopped for elevation of amylase, lipase or direct bilirubin above normal range. 